AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

This study tests a new drug called AZD0305 for people with a type of blood cancer called Multiple Myeloma (MM) that has come back or didn't get better after treatment. The study is in two phases, Phase I and Phase II. In Phase I, the study finds out how much of the drug is safe to give. In Phase II, it checks how well the drug works. AZD0305 will be tested alone and with other cancer medicines. People join if they are 18 or older and already tried at least three different treatments including a proteasome inhibitor, an immunomodulator, and an anti-CD38 antibody.

• Participants will need to visit the study center multiple times.
• Potential risks include the side effects from the drug.
• Compensation details for participation are not provided.

People can't join if they have certain health problems like asthma, heart disease, or other specific conditions. The study gives the drug through an IV, which is a way to get medicine directly into your blood. This study is open-label, meaning both the doctors and participants know the drug being given.

🧪💉